At the European Conference on Interventional Oncology (ECIO) meets International Liver Cancer Association (ILCA) session in Florence, Bruno Sangro, Pamplona, Spain, spoke on the alternatives to transarterial chemoembolization (TACE) and told delegates about the benefits of selective internal radiotherapy treatment. “Y90 radioembolization consistently produces disease control rates greater than 70%. It shows a favourable safety profile across BCLC stages and results in overall survival that compares well with TACE in the intermediate stage of liver cancer. Overall survival results with radioembolization also compare well with sorafenib in the advanced stage of the disease, and the therapy results in relevant overall survival among patients that are not candidates for TACE, or that progress after TACE. The available evidence is level 2A, and large randomised controlled trials are being conducted, particularly in the advanced stage,” he said.